Physiological effects of modulating the interleukin-6 axis

Rheumatology (United Kingdom)

Volumn 57, Issue , 2018, Pages ii43-ii50

  Schett, Georg ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

Cytokines Rheumatology key; Giant cell arteritis; Interleukin 6; Tocilizumab; Vasculitis

Indexed keywords

ANTIINFLAMMATORY AGENT; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; IL6 PROTEIN, HUMAN; IL6R PROTEIN, HUMAN;

ARTICLE; BIOLOGICAL FUNCTIONS; CYTOKINE PRODUCTION; DRUG TARGETING; HUMAN; IMMUNOMODULATION; INFLAMMATORY DISEASE; MULTICENTER STUDY (TOPIC); NONHUMAN; PATHOGENESIS; PHASE 3 CLINICAL TRIAL (TOPIC); PHYSIOLOGICAL PROCESS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIGNAL TRANSDUCTION; AUTOIMMUNE DISEASE; GIANT CELL ARTERITIS; PATHOPHYSIOLOGY; PHYSIOLOGY; RHEUMATOID ARTHRITIS;

ARTHRITIS, RHEUMATOID; AUTOIMMUNE DISEASES; GIANT CELL ARTERITIS; HUMANS; INTERLEUKIN-6; RECEPTORS, INTERLEUKIN-6; SIGNAL TRANSDUCTION;

EID: 85042614806     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kex513     Document Type: Article

References (105)

1. Hirano T, Yasukawa K, Harada H et al. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature 1986;324:43-50.
2. Naka T, Nishimoto N, Kishimoto T. The paradigm of IL-6: from basic science to medicine. Arthritis Res 2002;4(Suppl 3):S233-42.
3. Rose-John S. IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6. Int J Biol Sci 2012;8:1237-47.
4. Zilberstein A, Ruggieri R, Korn JH, Revel M. Structure and expression of cDNA and genes for human interferon-beta- 2, a distinct species inducible by growth-stimulatory cytokines. EMBO J 1986;5:2529-37.
5. Haegeman G, Content J, Volckaert G et al. Structural analysis of the sequence coding for an inducible 26-kDa protein in human fibroblasts. Eur J Biochem 1986;159:625-32.
6. Van Damme J, Opdenakker G, Simpson RJ et al. Identification of the human 26-kD protein, interferon beta 2 (IFN-beta 2), as a B cell hybridoma/plasmacytoma growth factor induced by interleukin 1 and tumor necrosis factor. J Exp Med 1987;165:914-9.
7. Nordan RP, Pumphrey JG, Rudikoff S. Purification and NH2-terminal sequence of a plasmacytoma growth factor derived from the murine macrophage cell line P388D1. J Immunol 1987;139:813-7.
8. Uyttenhove C, Coulie PG, Van Snick J. T cell growth and differentiation induced by interleukin-HP1/IL-6, the murine hybridoma/plasmacytoma growth factor. J Exp Med 1988;167:1417-27.
9. Gauldie J, Richards C, Harnish D, Lansdorp P, Baumann H. Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. Proc Natl Acad Sci USA 1987;84:7251-5.
10. Castell JV, Gomez-Lechon MJ, David M et al. Recombinant human interleukin-6 (IL-6/BSF-2/HSF) regulates the synthesis of acute phase proteins in human hepatocytes. FEBS Lett 1988;232:347-50.
11. Tanaka T, Narazaki M, Kishimoto T. IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol 2014;6:a016295.
12. Tanaka T, Kishimoto T. The biology and medical implications of interleukin-6. Cancer Immunol Res 2014;2:288-94.
13. Actemra (tocilizumab) [package insert]. South San Francisco, CA: Genentech, 2017.
14. Kimura A, Kishimoto T. IL-6: regulator of Treg/Th17 balance. Eur J Immunol 2010;40:1830-5.
15. Chomarat P, Banchereau J, Davoust J, Palucka AK. IL-6 switches the differentiation of monocytes from dendritic cells to macrophages. Nat Immunol 2000;1:510-4.
16. Pasare C, Medzhitov R. Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science 2003;299:1033-6.
17. Hurst SM, Wilkinson TS, McLoughlin RM et al. Il-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. Immunity 2001;14:705-14.
18. McLoughlin RM, Jenkins BJ, Grail D et al. IL-6 trans-signaling via STAT3 directs T cell infiltration in acute inflammation. Proc Natl Acad Sci USA 2005;102:9589-94.
19. Modur V, Li Y, Zimmerman GA, Prescott SM, McIntyre TM. Retrograde inflammatory signaling from neutrophils to endothelial cells by soluble interleukin-6 receptor alpha. J Clin Invest 1997;100:2752-6.
20. McLoughlin RM, Hurst SM, Nowell MA et al. Differential regulation of neutrophil-activating chemokines by IL-6 and its soluble receptor isoforms. J Immunol 2004;172:5676-83.
21. Narimatsu M, Maeda H, Itoh S et al. Tissue-specific autoregulation of the stat3 gene and its role in interleukin- 6-induced survival signals in T cells. Mol Cell Biol 2001;21:6615-25.
22. Teague TK, Schaefer BC, Hildeman D et al. Activationinduced inhibition of interleukin 6-mediated T cell survival and signal transducer and activator of transcription 1 signaling. J Exp Med 2000;191:915-26.
23. Curnow SJ, Scheel-Toellner D, Jenkinson W et al. Inhibition of T cell apoptosis in the aqueous humor of patients with uveitis by IL-6/soluble IL-6 receptor transsignaling. J Immunol 2004;173:5290-7.
24. Ma CS, Deenick EK, Batten M, Tangye SG. The origins, function, and regulation of T follicular helper cells. J Exp Med 2012;209:1241-53.
25. Tanaka T, Narazaki M, Kishimoto T. Therapeutic targeting of the interleukin-6 receptor. Annu Rev Pharmacol Toxicol 2012;52:199-219.
26. Heinrich PC, Castell JV, Andus T. Interleukin-6 and the acute phase response. Biochem J 1990;265:621-36.
27. Peters M, Blinn G, Jostock T et al. Combined interleukin 6 and soluble interleukin 6 receptor accelerates murine liver regeneration. Gastroenterology 2000;119:1663-71.
28. Wunderlich FT, Strohle P, Konner AC et al. Interleukin-6 signaling in liver-parenchymal cells suppresses hepatic inflammation and improves systemic insulin action. Cell Metab 2010;12:237-49.
29. Matthews VB, Allen TL, Risis S et al. Interleukin-6-deficient mice develop hepatic inflammation and systemic insulin resistance. Diabetologia 2010;53:2431-41.
30. Ellingsgaard H, Ehses JA, Hammar EB et al. Interleukin-6 regulates pancreatic alpha-cell mass expansion. Proc Natl Acad Sci USA 2008;105:13163-8.
31. Ellingsgaard H, Hauselmann I, Schuler B et al. Interleukin- 6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells. Nat Med 2011;17:1481-9.
32. Tamura T, Udagawa N, Takahashi N et al. Soluble interleukin- 6 receptor triggers osteoclast formation by interleukin 6. Proc Natl Acad Sci USA 1993;90:11924-8.
33. Tilg H, Moschen AR, Kaser A, Pines A, Dotan I. Gut, inflammation and osteoporosis: basic and clinical concepts. Gut 2008;57:684-94.
34. Marz P, Cheng JG, Gadient RA et al. Sympathetic neurons can produce and respond to interleukin 6. Proc Natl Acad Sci USA 1998;95:3251-6.
35. Marz P, Otten U, Rose-John S. Neural activities of IL-6- type cytokines often depend on soluble cytokine receptors. Eur J Neurosci 1999;11:2995-3004.
36. Yamauchi-Takihara K, Kishimoto T. Cytokines and their receptors in cardiovascular diseases-role of gp130 signalling pathway in cardiac myocyte growth and maintenance. Int J Exp Pathol 2000;81:1-16.
37. Terrell AM, Crisostomo PR, Wairiuko GM et al. Jak/STAT/ SOCS signaling circuits and associated cytokinemediated inflammation and hypertrophy in the heart. Shock 2006;26:226-34.
38. Wollert KC, Drexler H. The role of interleukin-6 in the failing heart. Heart Fail Rev 2001;6:95-103.
39. Scheller J, Garbers C, Rose-John S. Interleukin-6: from basic biology to selective blockade of pro-inflammatory activities. Semin Immunol 2014;26:2-12.
40. Scheller J, Rose-John S. Interleukin-6 and its receptor: from bench to bedside. Med Microbiol Immunol 2006;195:173-83.
41. Rose-John S, Scheller J, Elson G, Jones SA. Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer. J Leukoc Biol 2006;80:227-36.
42. Narazaki M, Yasukawa K, Saito T et al. Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130. Blood 1993;82:1120-6.
43. Rose-John S, Heinrich PC. Soluble receptors for cytokines and growth factors: generation and biological function. Biochem J 1994;300(Pt 2):281-90.
44. Lust JA, Donovan KA, Kline MP et al. Isolation of an mRNA encoding a soluble form of the human interleukin-6 receptor. Cytokine 1992;4:96-100.
45. Matthews V, Schuster B, Schutze S et al. Cellular cholesterol depletion triggers shedding of the human interleukin-6 receptor by ADAM10 and ADAM17 (TACE). J Biol Chem 2003;278:38829-39.
46. Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S. The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta 2011;1813:878-88.
47. Fischer M, Goldschmitt J, Peschel C et al. I. A bioactive designer cytokine for human hematopoietic progenitor cell expansion. Nat Biotechnol 1997;15:142-5.
48. Jostock T, Mullberg J, Ozbek S et al. Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses. Eur J Biochem 2001;268:160-7.
49. Nakahara H, Song J, Sugimoto M et al. Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. Arthritis Rheum 2003;48:1521-9.
50. Grossman RM, Krueger J, Yourish D et al. Interleukin 6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes. Proc Natl Acad Sci USA 1989;86:6367-71.
51. Duncan MR, Berman B. Stimulation of collagen and glycosaminoglycan production in cultured human adult dermal fibroblasts by recombinant human interleukin 6. J Invest Dermatol 1991;97:686-92.
52. Hirano T, Matsuda T, Turner M et al. Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis. Eur J Immunol 1988;18:1797-801.
53. Yoshizaki K, Matsuda T, Nishimoto N et al. Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease. Blood 1989;74:1360-7.
54. Mori S, Koga Y. Glucocorticoid-resistant polymyalgia rheumatica: pretreatment characteristics and tocilizumab therapy. Clin Rheumatol 2016;35:1367-75.
55. Dasgupta B, Panayi GS. Interleukin-6 in serum of patients with polymyalgia rheumatica and giant cell arteritis. Br J Rheumatol 1990;29:456-8.
56. Roche NE, Fulbright JW, Wagner AD et al. Correlation of interleukin-6 production and disease activity in polymyalgia rheumatica and giant cell arteritis. Arthritis Rheum 1993;36:1286-94.
57. Weyand CM, Hicok KC, Hunder GG, Goronzy JJ. Tissue cytokine patterns in patients with polymyalgia rheumatica and giant cell arteritis. Ann Intern Med 1994;121:484-91.
58. Nishimoto N, Yoshizaki K, Tagoh H et al. Elevation of serum interleukin 6 prior to acute phase proteins on the inflammation by surgical operation. Clin Immunol Immunopathol 1989;50:399-401.
59. Gillmore JD, Lovat LB, Persey MR, Pepys MB, Hawkins PN. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet 2001;358:24-9.
60. Nemeth E, Rivera S, Gabayan V et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 2004;113:1271-6.
61. Hashizume M, Hayakawa N, Mihara M. IL-6 trans-signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF-a and IL- 17. Rheumatology 2008;47:1635-40.
62. Kotake S, Sato K, Kim KJ et al. Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast- like cell formation. J Bone Miner Res 1996;11:88-95.
63. Poli V, Balena R, Fattori E et al. Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion. EMBO J 1994;13:1189-96.
64. Chrousos GP. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N Engl J Med 1995;332:1351-62.
65. Tsigos C, Chrousos GP. Hypothalamic-pituitary-adrenal axis, neuroendocrine factors and stress. J Psychosom Res 2002;53:865-71.
66. Papanicolaou DA, Wilder RL, Manolagas SC, Chrousos GP. The pathophysiologic roles of interleukin-6 in human disease. Ann Intern Med 1998;128:127-37.
67. Khovidhunkit W, Kim MS, Memon RA et al. Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J Lipid Res 2004;45:1169-96.
68. Katsume A, Saito H, Yamada Y et al. Anti-interleukin 6 (IL- 6) receptor antibody suppresses Castleman's disease like symptoms emerged in IL-6 transgenic mice. Cytokine 2002;20:304-11.
69. Ohshima S, Saeki Y, Mima T et al. Interleukin 6 plays a key role in the development of antigen-induced arthritis. Proc Natl Acad Sci USA 1998;95:8222-6.
70. Fujimoto M, Serada S, Mihara M et al. Interleukin-6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responses. Arthritis Rheum 2008;58:3710-9.
71. Alonzi T, Fattori E, Lazzaro D et al. Interleukin 6 is required for the development of collagen-induced arthritis. J Exp Med 1998;187:461-8.
72. Kitaba S, Murota H, Terao M et al. Blockade of interleukin- 6 receptor alleviates disease in mouse model of scleroderma. Am J Pathol 2012;180:165-76.
73. Serada S, Fujimoto M, Mihara M et al. IL-6 blockade inhibits the induction of myelin antigen-specific Th17 cells and Th1 cells in experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA 2008;105:9041-6.
74. Haruta H, Ohguro N, Fujimoto M et al. Blockade of interleukin- 6 signaling suppresses not only Th17 but also interphotoreceptor retinoid binding protein-specific Th1 by promoting regulatory T cells in experimental autoimmune uveoretinitis. Invest Ophthalmol Vis Sci 2011;52:3264-71.
75. Okiyama N, Sugihara T, Iwakura Y et al. Therapeutic effects of interleukin-6 blockade in a murine model of polymyositis that does not require interleukin-17A. Arthritis Rheum 2009;60:2505-12.
76. Song SN, Tomosugi N, Kawabata H et al. Down-regulation of hepcidin resulting from long-term treatment with an anti-IL-6 receptor antibody (tocilizumab) improves anemia of inflammation in multicentric Castleman disease. Blood 2010;116:3627-34.
77. Madhok R, Crilly A, Watson J, Capell HA. Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity. Ann Rheum Dis 1993;52:232-4.
78. Lepore L, Pennesi M, Saletta S et al. Study of IL-2, IL-6, TNFa, IFNg and b in the serum and synovial fluid of patients with juvenile chronic arthritis. Clin Exp Rheumatol 1994;12:561-5.
79. Spirchez M, Samasca G, Iancu M, Bolba C, Miu N. Relation of interleukin-6, TNF-a and interleukin-1a with disease activity and severity in juvenile idiopathic arthritis patients. Clin Lab 2012;58:253-60.
80. Barnes TC, Anderson ME, Moots RJ. The many faces of interleukin-6: the role of IL-6 in inflammation, vasculopathy, and fibrosis in systemic sclerosis. Int J Rheumatol 2011;2011:721608.
81. Weyand CM, Goronzy JJ. Immune mechanisms in medium and large-vessel vasculitis. Nat Rev Rheumatol 2013;9:731-40.
82. Salvarani C, Cantini F, Boiardi L, Hunder GG. Laboratory investigations useful in giant cell arteritis and Takayasu's arteritis. Clin Exp Rheumatol 2003;21(6 Suppl 32):S23-8.
83. Weyand CM, Fulbright JW, Hunder GG, Evans JM, Goronzy JJ. Treatment of giant cell arteritis: interleukin-6 as a biologic marker of disease activity. Arthritis Rheum 2000;43:1041-8.
84. Nishimoto N, Kanakura Y, Aozasa K et al. Humanized antiinterleukin- 6 receptor antibody treatment of multicentric Castleman disease. Blood 2005;106:2627-32.
85. Tanaka T, Narazaki M, Ogata A, Kishimoto T. A new era for the treatment of inflammatory autoimmune diseases by interleukin-6 blockade strategy. Semin Immunol 2014;26:88-96.
86. Richez C, Barnetche T, Khoryati L et al. Tocilizumab treatment decreases circulating myeloid dendritic cells and monocytes, 2 components of the myeloid lineage. J Respir Dis 2012;39:1192-7.
87. Kasama T, Isojima S, Umemura M et al. Serum macrophage migration inhibitory factor levels are correlated with response to tocilizumab therapy in patients with rheumatoid arthritis. Rheumatol Int 2013;34:429-33.
88. Samson M, Audia S, Janikashvili N et al. Brief report: inhibition of interleukin-6 function corrects Th17/Treg cell imbalance in patients with rheumatoid arthritis. Arthritis Rheum 2012;64:2499-503.
89. Pesce B, Soto L, Sabugo F et al. Effect of interleukin-6 receptor blockade on the balance between regulatory T cells and T helper type 17 cells in rheumatoid arthritis patients. Clin Exp Immunol 2013;171:237-42.
90. Stubenrauch K, Wessels U, Birnboeck H et al. Subset analysis of patients experiencing clinical events of a potentially immunogenic nature in the pivotal clinical trials of tocilizumab for rheumatoid arthritis: evaluation of an antidrug antibody ELISA using clinical adverse eventdriven immunogenicity testing. Clin Ther 2010;32: 1597-609.
91. Roll P, Muhammad K, Schumann M et al. In vivo effects of the anti-interleukin-6 receptor inhibitor tocilizumab on the B cell compartment. Arthritis Rheum 2011;63:1255-64.
92. Snir A, Kessel A, Haj T et al. Anti-IL-6 receptor antibody (tocilizumab): a B cell targeting therapy. Clin Exp Rheumatol 2011;29:697-700.
93. Benucci M, Meacci F, Grossi V et al. Correlations between immunogenicity, drug levels, and disease activity in an Italian cohort of rheumatoid arthritis patients treated with tocilizumab. Biologics 2016;10:53-8.
94. Sigaux J, Hamze M, Daien C et al. Immunogenicity of tocilizumab in patients with rheumatoid arthritis. Joint Bone Spine 2017;84:39-45.
95. Kneepkens EL, van den Oever I, Plasencia CH et al. Serum tocilizumab trough concentration can be used to monitor systemic IL-6 receptor blockade in patients with rheumatoid arthritis: a prospective observational cohort study. Scand J Rheumatol 2017;46:87-94.
96. Unizony S, Arias-Urdaneta L, Miloslavsky E et al. Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica. Arthritis Care Res 2012;64:1720-9.
97. Loricera J, Blanco R, Hernandez JL et al. Tocilizumab in giant cell arteritis: multicenter open-label study of 22 patients. Semin Arthritis Rheum 2015;44:717-23.
98. Beyer C, Axmann R, Sahinbegovic E et al. Anti-interleukin 6 receptor therapy as rescue treatment for giant cell arteritis. Ann Rheum Dis 2011;70:1874-5.
99. Seitz M, Reichenbach S, Bonel HM et al. Rapid induction of remission in large vessel vasculitis by IL-6 blockade. A case series. Swiss Med Wkly 2011;141:w13156.
100. Unizony SH, Dasgupta B, Fisheleva E et al. Design of the tocilizumab in giant cell arteritis trial. Int J Rheumatol 2013;2013:912562.
101. Stone JH, Tuckwell K, Dimonako S et al. Efficacy and safety of tocilizumab in patients with giant cell arteritis: primary and secondary outcomes from a phase 3, randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol 2017;68(Suppl 10):abstract 911.
102. Schiff MH, Kremer JM, Jahreis A et al. Integrated safety in tocilizumab clinical trials. Arthritis Res Ther 2011;13:R141.
103. Genovese MC, Rubbert-Roth A, Smolen JS et al. Longterm safety and efficacy of tocilizumab in patients with rheumatoid arthritis: a cumulative analysis of up to 4.6 years of exposure. J Rheumatol 2013;40:768-80.
104. Hunter CA, Jones SA. IL-6 as a keystone cytokine in health and disease. Nat Immunol 2015;16:448-57.
105. Calabrese LH, Rose-John S. IL-6 biology: implications for clinical targeting in rheumatic disease. Nat Rev Rheumatol 2014;10:720-7.